Page 51 - Read Online

Anugwom et al. Hepatoma Res 2022;8:7 https://dx.doi.org/10.20517/2394-5079.2021.123 Page 11 of 13

systematic review. World J Gastroenterol 2015;21:11185-98. DOI PubMed PMC
13. Bodzin AS, Lunsford KE, Markovic D, Harlander-Locke MP, Busuttil RW, Agopian VG. Predicting mortality in patients developing
recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics. Ann Surg
2017;266:118-25. DOI PubMed
14. Guerrini GP, Berretta M, Tarantino G, et al. Multimodal oncological approach in patients affected by recurrent hepatocellular
carcinoma after liver transplantation. Eur Rev Med Pharmacol Sci 2017;21:3421-35. PubMed
15. Couzin J. Cancer immunotherapy. Select T cells, given space, shrink tumors. Science 2002;297:1973. DOI PubMed
16. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl
Cancer Inst 2011;103:117-28. DOI PubMed PMC
17. Cheng A, Kang Y, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular
carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34. DOI PubMed
18. Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med 2008;359:378-90. DOI
19. Lué A, Serrano MT, Bustamante FJ, et al. Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular
carcinoma administered sorafenib. Oncotarget 2017;8:103077-86. DOI PubMed PMC
20. Sultan A, Anugwom CM, Wondifraw Z, Braimoh GA, Bane A, Debes JD. Single center analysis of therapy and outcomes of
hepatocellular carcinoma in Sub-Saharan Africa. Expert Rev Gastroenterol Hepatol 2020;14:1007-11. DOI PubMed PMC
21. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK
pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109. DOI PubMed
22. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment
(RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66. DOI PubMed
23. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J
Med 2018;379:54-63. DOI PubMed PMC
24. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular
carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73. DOI PubMed
25. Zhu AX, Park JO, Ryoo B, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular
carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol
2015;16:859-70. DOI PubMed
26. Yoong KF, McNab G, Hübscher SG, Adams DH. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating
lymphocytes to tumor endothelium in human hepatocellular carcinoma. J Immunol 1998;160:3978-88. PubMed
27. Hui E. Immune checkpoint inhibitors. J Cell Biol 2019;218:740-1. DOI PubMed PMC
28. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013;13:227-42. DOI PubMed
PMC
29. Gutierrez C, McEvoy C, Reynolds D, Nates JL. Toxicity of immunotherapeutic agents. Crit Care Clin 2021;37:605-24. DOI PubMed
30. El-khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-
label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502. DOI PubMed PMC
31. Finn RS, Ryoo BY, Merle P, et al; KEYNOTE-240 investigators. Pembrolizumab as second-line therapy in patients with advanced
hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 2020;38:193-202. DOI
PubMed
32. Yau T, Park J, Finn R, et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as
first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol 2019;30:v874-5. DOI
33. Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
N Engl J Med 2020;382:1894-905. DOI PubMed
34. Ren Z, Fan J, Xu J, et al. LBA2 Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular
carcinoma (ORIENT-32)2. Ann Oncol 2020;31:S1287. DOI
35. Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol
Hepatol 2021;18:525-43. DOI PubMed PMC
36. Huang H, Lu Y, Zhou T, Gu G, Xia Q. Innate immune cells in immune tolerance after liver transplantation. Front Immunol
2018;9:2401. DOI PubMed PMC
37. Thomson AW, Knolle PA. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol 2010;10:753-66.
DOI PubMed
38. de la Garza RG, Sarobe P, Merino J, et al. Trial of complete weaning from immunosuppression for liver transplant recipients: factors
predictive of tolerance. Liver Transpl 2013;19:937-44. DOI PubMed
39. Feng S, Bucuvalas JC, Mazariegos GV, et al. Efficacy and safety of immunosuppression withdrawal in pediatric liver transplant
recipients: moving toward personalized management. Hepatology 2021;73:1985-2004. DOI PubMed
40. Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation of the liver in humans. Surg
Gynecol Obstet 1963;117:659-76. PubMed PMC
41. Starzl TE, Marchioro TL, Waddell WR. The reversal of rejection in human renal homografts with subsequent development of
homograft tolerance. Surg Gynecol Obstet 1963;117:385-95. PubMed PMC
42. Eason JD, Loss GE, Blazek J, Nair S, Mason AL. Steroid-free liver transplantation using rabbit antithymocyte globulin induction:
results of a prospective randomized trial. Liver Transpl 2001;7:693-7. DOI PubMed